Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

496 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Elotuzumab, lenalidomide, and dexamethasone as salvage therapy for patients with multiple myeloma: Italian, multicenter, retrospective clinical experience with 300 cases outside of controlled clinical trials.
Gentile M, Specchia G, Derudas D, Galli M, Botta C, Rocco S, Conticello C, Califano C, Giuliani N, Mangiacavalli S, Attingenti E, Lombardo A, Brunori M, Rossi E, Antonioli E, Ria R, Zambello R, Di Renzo N, Mele G, Marcacci G, Musto P, Capalbo S, Cascavilla N, Cerchione C, Belotti A, Criscuolo C, Uccello G, Curci P, Vigna E, Fraticelli V, Vincelli D, Bonalumi A, Siniscalchi A, Stocchi R, Martino M, Ballanti S, Gangemi D, Gagliardi A, Gamberi B, Pompa A, Recchia AG, Tripepi G, Pitino A, Frigeri F, Consoli U, Bringhen S, Zamagni E, Patriarca F, De Stefano V, Di Raimondo F, Palmieri S, Petrucci MT, Offidani M, Boccadoro M, Cavo M, Morabito F. Gentile M, et al. Among authors: gagliardi a. Haematologica. 2021 Jan 1;106(1):291-294. doi: 10.3324/haematol.2019.241513. Haematologica. 2021. PMID: 32107338 Free PMC article. No abstract available.
Elotuzumab plus lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: Extended 3-year follow-up of a multicenter, retrospective clinical experience with 319 cases outside of controlled clinical trials.
Bruzzese A, Derudas D, Galli M, Martino EA, Rocco S, Conticello C, Califano C, Giuliani N, Mangiacavalli S, Farina G, Lombardo A, Brunori M, Rossi E, Antonioli E, Ria R, Zambello R, Di Renzo N, Mele G, Marcacci G, Pietrantuono G, Palumbo G, Cascavilla N, Cerchione C, Belotti A, Criscuolo C, Uccello G, Curci P, Vigna E, Mendicino F, Iaccino E, Mimmi S, Botta C, Vincelli D, Sgherza N, Bonalumi A, Cupelli L, Stocchi R, Martino M, Ballanti S, Gangemi D, Gagliardi A, Gamberi B, Pompa A, Tripepi G, Frigeri F, Consoli U, Bringhen S, Zamagni E, Patriarca F, De Stefano V, Di Raimondo F, Palmieri S, Petrucci MT, Offidani M, Musto P, Boccadoro M, Cavo M, Neri A, Morabito F, Gentile M. Bruzzese A, et al. Among authors: gagliardi a. Hematol Oncol. 2022 Oct;40(4):704-715. doi: 10.1002/hon.3031. Epub 2022 Jun 1. Hematol Oncol. 2022. PMID: 35608183 Free article.
KRD (carfilzomib and lenalidomide plus dexamethasone) for the treatment of relapsed or refractory multiple myeloma in the real-life: a retrospective survey in 123 patients.
Palmieri S, Rocco S, Vitagliano O, Catalano L, Cerchione C, Vincelli ID, Scopelliti A, Gentile M, Farina G, Barone M, Gagliardi A, Esposito D, Arcamone M, Amico V, Fontana R, Sementa A, Sica A, Svanera G, Pane F, Ferrara F. Palmieri S, et al. Among authors: gagliardi a. Ann Hematol. 2020 Dec;99(12):2903-2909. doi: 10.1007/s00277-020-04158-4. Epub 2020 Jun 25. Ann Hematol. 2020. PMID: 32583088
Is re-challenge still an option as salvage therapy in multiple myeloma? The case of REal-life BOrtezomib re-Use as secoND treatment for relapsed patients exposed frontline to bortezomib-based therapies (the REBOUND Study).
Musto P, Simeon V, Cascavilla N, Falcone A, Petrucci MT, Cesini L, Di Raimondo F, Conticello C, Ria R, Catalano L, Salvatore D, Mastrullo L, Gagliardi A, Villani O, Pietrantuono G, D'Arena G, Mansueto G, Bringhen S, Genuardi M, Di Renzo N, Reddiconto G, Fragasso A, Caravita T, Scapicchio D, Marziano G, Boccadoro M, Mangiacavalli S, Corso A. Musto P, et al. Among authors: gagliardi a. Ann Hematol. 2019 Feb;98(2):361-367. doi: 10.1007/s00277-018-3524-1. Epub 2018 Oct 23. Ann Hematol. 2019. PMID: 30353388
[Role of alpha-interferon in the therapy of essential thrombocythemia].
Lazzarino M, Vitale A, Morra E, Gagliardi A, Bernasconi P, Torromeo C, Inverardi D, Burgio VL, Castello A, Bernasconi C, et al. Lazzarino M, et al. Among authors: gagliardi a. Haematologica. 1990 Jul-Aug;75 Suppl 4:41-7. Haematologica. 1990. PMID: 2074053 Review. Italian. No abstract available.
Combined use of free light chain and heavy/light chain ratios allow diagnosis and monitoring of patients with monoclonal gammopathies: Experience of a single institute, with three exemplar case reports.
Gagliardi A, Carbone C, Russo A, Cuccurullo R, Lucania A, Cioppa PD, Misso G, Caraglia M, Tommasino C, Mastrullo L. Gagliardi A, et al. Oncol Lett. 2016 Oct;12(4):2363-2370. doi: 10.3892/ol.2016.4965. Epub 2016 Aug 5. Oncol Lett. 2016. PMID: 27698801 Free PMC article.
Therapy of essential thrombocythemia with alpha-interferon: results and prospects.
Lazzarino M, Vitale A, Morra E, Gagliardi A, Bernasconi P, Torromeo C, Inverardi D, Burgio VL, Castello A, Bernasconi C, et al. Lazzarino M, et al. Among authors: gagliardi a. Eur J Haematol Suppl. 1990;52:15-21. doi: 10.1111/j.1600-0609.1990.tb00899.x. Eur J Haematol Suppl. 1990. PMID: 2279539 Review.
Referral patterns for common surgical procedures in Ontario: a cross-sectional population-level study.
Seyedi P, Aleman D, Baxter N, Bell C, Bodur M, Calzavara A, Campbell R, Carter M, de Jager P, Emerson S, Gagliardi A, Irish J, Martin D, Lee S, Saxe-Braithwaite M, Takata J, Yang S, Zanchetta C, Urbach D. Seyedi P, et al. Among authors: gagliardi a. Can J Surg. 2024 Dec 13;67(6):E397-E405. doi: 10.1503/cjs.002324. Print 2024 Nov-Dec. Can J Surg. 2024. PMID: 39672555
496 results